{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:06:11Z","timestamp":1781953571482,"version":"3.54.5"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":1011,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.exphem.2019.08.007","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T11:46:24Z","timestamp":1567597584000},"page":"36-40.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia"],"prefix":"10.1016","volume":"77","author":[{"given":"Orlando","family":"Antelope","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem A.","family":"Vellore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Pomicter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria","family":"Van Scoyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip M.","family":"Clair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"O'Hare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2019.08.007_bib0001","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2019.08.007_bib0002","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE Trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2019.08.007_bib0003","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1080\/10428194.2017.1379074","article-title":"First-line therapy for chronic phase CML: Selecting the optimal BCR-ABL1-targeted TKI","volume":"59","author":"Saglio","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2019.08.007_bib0004","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2019.08.007_bib0005","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2019.08.007_bib0006","doi-asserted-by":"crossref","first-page":"E125","DOI":"10.1002\/ajh.23338","article-title":"Three novel patient-derived BCR\/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors","volume":"87","author":"Redaelli","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2019.08.007_bib0007","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","article-title":"Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of \u03b1-synuclein in Parkinsons disease models","volume":"22","author":"Hebron","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.exphem.2019.08.007_bib0008","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JPD-160867","article-title":"Nilotinib effects in Parkinson's disease and dementia with Lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.exphem.2019.08.007_bib0009","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3324\/haematol.2017.182022","article-title":"Present results and future perspectives in optimizing chronic myeloid leukemia therapy","volume":"103","author":"Carella","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2019.08.007_bib0010","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/leu.2014.326","article-title":"PF-114, a potent and selective inhibitor of native and mutated BCR\/ABL, is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation","volume":"29","author":"Mian","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2019.08.007_bib0011","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood-2018-99-119142","article-title":"Safety and efficacy of HQP1351, a 3rd generation oral BCR-ABL inhibitor in patients with tyrosine kinase inhibitor-resistant chronic myelogenous leukemia: Preliminary results of phase 1 study","volume":"132","author":"Jiang","year":"2018","journal-title":"Blood"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X19309506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X19309506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:34:25Z","timestamp":1759566865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X19309506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":11,"alternative-id":["S0301472X19309506"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2019.08.007","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2019.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}